Novo's full results for Wegovy in children ages 6 to under 12 with obesity are the kind of data that deserves a serious hearing. The company reported that the injection lowered body mass index by an estimated 19.7 percentage points on average compared with placebo at 68 weeks when patients stayed on treatment, with BMI falling 17.4% in the drug group and rising 2.2% in the placebo group. Those are striking numbers for a population with almost no approved medication options.

The figures also need careful reading. When all 167 children were counted, including those who stopped treatment, the average advantage over placebo shrank to 16.2 percentage points. That gap matters. Every child in the study also received lifestyle changes, including a reduced-calorie diet and more physical activity, so the drug's effect cannot be separated cleanly from the broader program. Readers should keep both the optimistic and the adjusted figures in view.

The disease context explains why the company's case has force. Dr. Andrea Traina, Novo's medical director lead of obesity, described a "very significant disease burden" in very young patients. The World Obesity Federation estimates roughly 177 million children and teens ages 5 to 19 were affected in 2025, a figure projected to reach 228 million by 2040. Nearly half of the trial children already had at least one complication, such as high blood pressure, high cholesterol or sleep apnea. If a drug can reduce that burden early, the public interest is clear.

Still, the study has limits that the marketing language should not hide. Novo said the drug's safety and tolerability were consistent with adult trials and that it observed no safety concerns related to growth or pubertal development. Those are reassuring findings, but the two-year study does not show whether treating obesity earlier changes the long-term course of the disease. Traina herself called this an "evidence gap" and pointed to future research.

My conclusion is that regulators and families should treat these results as a strong reason for longer, independent follow-up, not as a settled answer. Children are the group where lifelong effects matter most, and the trial cannot yet say what treatment or maintenance will look like as they grow into adulthood. Approval decisions should rest on that fuller evidence, and the next data release should be judged on whether it closes the gap Traina described.